Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
RCUS
#1597
Arcus Biosciences, Inc.
20.3
8
+4.57%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+4.57%
Changement Mensuel
-12.53%
Evolution sur 6 mois
+92.26%
Changement Annuel
+96.53%
Clôture Précédente
19.4
9
Open
20.1
5
Bid
Ask
Low
20.0
7
High
20.4
4
Volume
601
Marchés
Actions des Marchés US
Soins de Santé
RCUS
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
91.51 M
105.84 M
105.89 M
106.43 M
107.97 M
125.35 M
—
Valuation ratios
Enterprise value
1.2 B
1.43 B
639.2 M
618.35 M
1.23 B
2.77 B
5.25 B
Price to earnings ratio
-4.85
-4.74
-1.86
-2.54
-3.91
-7.24
-15.54
Price to sales ratio
5.01
5.2
5.14
3.13
5.86
10.36
24.5
Price to cash flow ratio
7.8
7.89
2.45
2.38
2.95
5.31
13.1
Price to book ratio
0.55
2.77
0.33
0.37
0.68
4.06
5.43
Enterprise value to EBITDA ratio
-3.49
-4.02
-1.39
-1.73
-3.15
-6.93
-13.2
Profitability ratios
Return on assets %
0.07
0.08
0.1
0
0.14
0.09
0.33
Return on equity %
0.16
0.19
0.21
0
0.31
0.17
0.69
Return on invested capital %
133.76
133.41
165.7
—
198.95
160.28
—
Gross margin %
100
100
100
100
100
100
400
Operating margin %
218.75
396.15
435.71
5
546.15
345.45
1 332.32
EBITDA margin %
-231.25
-419.23
-450
-6.88
-557.69
-354.55
-1 369.11
Net margin %
191.67
361.54
400
0
519.23
321.21
1 240.44
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
5.24
4.5
5.37
4.5
3.65
4.36
17.88
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.02
0.02
0.14
0.03
0.03
0.22
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.04
0.04
0.04
0.09
0.1
0.09
0.32
Long term debt to total equity ratio
0.08
0.1
0.09
0.18
0.22
0.16
0.65
Per share metrics
Operating cash flow per share
-0.28
1.11
1.34
1.25
0.91
1.12
4.62
EBIT per share
-1.15
-1.14
-1.24
-0.08
-1.33
-1.06
-3.71
EBITDA per share
-1.21
-1.21
-1.28
-0.1
-1.36
-1.09
-3.83
Total debt per share
—
—
—
—
—
—
—
Cash per share
11.91
10.85
10.13
8.55
7.8
9.13
35.62
Net current asset value per share
12.33
11.28
10.48
8.88
8.05
9.38
36.78
Tangible book value per share
6.18
5.38
5.4
5.15
4.09
5.88
20.52
Working capital per share
9.98
8.77
8.53
6.91
5.84
7.23
28.5
Book value per share
6.18
5.38
5.4
5.15
4.09
5.88
20.52
Nouvelles
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Présentation Arcus 2025 : les données de casdatifan se renforcent, le pipeline I&I émerge
Arcus 2025 presentation: casdatifan data strengthens, I&I pipeline emerges
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates
Arcus Biosciences sous les projecteurs : résultats d’essai d’un médicament rénal en jeu
Arcus Biosciences in spotlight: Kidney drug trial results at stake